What Will We Expect From Novel Therapies to Esophageal and Gastric Malignancies?

Ramon Andrade De Mello, Luis Castelo-Branco, Pedro Castelo-Branco, Daniel Humberto Pozza, Louis Vermeulen, Sofia Palacio, Matthew Salzberg, Albert Lockhart

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Esophageal cancer and gastric cancer are aggressive diseases for which treatment approaches are facing a new era. Some molecular pathways, such as VEGF, EGFR, fibroblast growth factor receptor, PIK3CA, and PARP-1, have been studied, and novel targeted drugs are presumed to be developed in the near future. From The Cancer Genome Atlas report, 80% of Epstein-Barr virus tumors and 42% of tumors with microsatellite instability have PIK3CA mutations, suggesting that this pathway could be reevaluated as a possible target for new systemic treatment of gastric cancer. Notably, higher PARP-1 expression can be found in gastric cancer, which might be related to more advanced disease and worse prognosis. In addition, PD-L1 expression, high microsatellite instability, and mismatch repair deficiency can be found in gastric cancer, thus suggesting that immunotherapy may also play a role in those patients. We discuss trends related to the potential of novel therapies for patients with esophageal and gastric cancers in the near future.

Original languageEnglish (US)
Pages (from-to)249-261
Number of pages13
JournalAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Issue number38
DOIs
StatePublished - May 23 2018

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'What Will We Expect From Novel Therapies to Esophageal and Gastric Malignancies?'. Together they form a unique fingerprint.

Cite this